Who are Oral Anticoagulant's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Bevyxxa, Savaysa, Eliquis, Xarelto, APIXABAN, RIVAROXABAN.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/oral-anticoagulant.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Oral Anticoagulant — Competitive Intelligence Brief

Oral Anticoagulant (oral-anticoagulant) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Direct oral anticoagulant (DOAC); Factor Xa inhibitor. Area: Cardiovascular.

discontinued Direct oral anticoagulant (DOAC); Factor Xa inhibitor Factor Xa (coagulation Factor X, activated form) Cardiovascular Live · refreshed every 30 min

Target snapshot

Oral Anticoagulant (oral-anticoagulant) — Pfizer Inc.. Inhibits Factor Xa to block the intrinsic and extrinsic coagulation pathways, preventing thrombin generation and clot formation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Oral Anticoagulant TARGET	oral-anticoagulant	Pfizer Inc.	discontinued	Direct oral anticoagulant (DOAC); Factor Xa inhibitor	Factor Xa (coagulation Factor X, activated form)
Bevyxxa	BETRIXABAN	Portola Pharms Inc	marketed	Factor Xa Inhibitor	Coagulation factor X	2017-01-01
Savaysa	edoxaban	Daiichi Sankyo Inc	marketed	Factor Xa Inhibitor	Coagulation factor X	2015-01-01
Eliquis	apixaban	Bristol-Myers Squibb	marketed	Factor Xa inhibitor	Factor Xa (FXa)	2012-01-01
Xarelto	rivaroxaban	Johnson & Johnson	marketed	Direct Factor Xa Inhibitor	Factor Xa (FXa)	2011-01-01
APIXABAN	APIXABAN		marketed	Factor Xa Inhibitor [EPC]		2011-01-01
RIVAROXABAN	RIVAROXABAN		marketed	Factor Xa Inhibitor [EPC]		2008-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2034-02-17 — Xarelto · 9539218 · Method of Use · US
2034-08-17 — Xarelto · 9539218*PED · Compound · US

Sponsor landscape (Direct oral anticoagulant (DOAC); Factor Xa inhibitor class)

Pfizer Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Oral Anticoagulant — Competitive Intelligence Brief. https://druglandscape.com/ci/oral-anticoagulant. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab